Midatech Pharma plc (MTP)
$0.2851
Rating:
Recommendation:
Buy
| Symbol | MTP |
|---|---|
| Price | $0.2851 |
| Beta | 1.219 |
| Volume Avg. | 1.84M |
| Market Cap | 1.977M |
| Shares () | - |
| 52 Week Range | 0.19-20.8 |
| 1y Target Est | - |
| DCF Unlevered | MTP DCF -> | |
|---|---|---|
| DCF Levered | MTP LDCF -> | |
| ROE | -112.47% | Strong Sell |
| ROA | -138.57% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | 19.73% | Neutral |
| P/E | -0.14 | Neutral |
| P/B | - |
Latest MTP news
About
Download (Excel)Midatech Pharma plc, a drug delivery technology company, focuses on the research and development of medicines in the United Kingdom, rest of Europe, and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTX114, an immuno-suppressant for topical application in psoriasis; MTD211, a long-acting formulation of brexpiprazole for the treatment of schizophrenia and adjunctive treatment of major depressive disorder; and MTD219, a long-acting formulation of tacrolimus used to lower the risk of organ transplant rejection. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. The company was founded in 2000 and is headquartered in Cardiff, the United Kingdom.